Stratos Wealth Partners LTD. Trims Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Stratos Wealth Partners LTD. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 79,417 shares of the biopharmaceutical company's stock after selling 4,597 shares during the period. Stratos Wealth Partners LTD.'s holdings in Gilead Sciences were worth $8,899,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Proficio Capital Partners LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth about $339,000. Personal CFO Solutions LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth about $207,000. Johnson Investment Counsel Inc. raised its position in shares of Gilead Sciences by 10.3% in the 4th quarter. Johnson Investment Counsel Inc. now owns 16,629 shares of the biopharmaceutical company's stock worth $1,536,000 after acquiring an additional 1,549 shares in the last quarter. Finally, Independent Advisor Alliance raised its position in shares of Gilead Sciences by 35.4% in the 4th quarter. Independent Advisor Alliance now owns 32,128 shares of the biopharmaceutical company's stock worth $2,968,000 after acquiring an additional 8,398 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $330,510.00. Following the transaction, the insider owned 120,168 shares in the company, valued at $13,238,908.56. The trade was a 2.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer owned 615,725 shares in the company, valued at approximately $68,006,826.25. This represents a 1.60% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 58,500 shares of company stock valued at $6,340,745. Insiders own 0.27% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on GILD. Oppenheimer lowered their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Morgan Stanley boosted their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Nine analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $111.38.

Gilead Sciences Price Performance

GILD stock traded up $1.30 during mid-day trading on Thursday, hitting $114.54. 6,096,837 shares of the stock were exchanged, compared to its average volume of 7,706,475. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The business has a fifty day moving average price of $107.40 and a 200 day moving average price of $104.35. Gilead Sciences, Inc. has a 12 month low of $68.14 and a 12 month high of $119.96. The stock has a market capitalization of $142.48 billion, a price-to-earnings ratio of 24.11, a PEG ratio of 0.73 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the company posted ($1.32) EPS. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.76%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.